Mamoru Fukuda, MD

Articles by Mamoru Fukuda, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

ByMamoru Fukuda, MD,Susumu Yamaguchi, MD,Tomohiko Ohta, MD,Yoshiaki Nakayama, MD,Haruki Ogata, MD,Kaname Shimizu, MD,Toru Nishikawa, MD,Yukihiro Adachi, MD,Eisuke Fukuma, MD

July 1st 1999

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as

Latest Updated Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen
July 1st 1999

Mamoru Fukuda, MD

Articles by Mamoru Fukuda, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

Latest Updated Articles

Trending on CancerNetwork

Atezolizumab/Chemo Earns FDA Priority Review in Stage III dMMR/MSI-H Colon Cancer

69 Assessing the Impact and Efficacy of Anthracyclines and Trastuzumab Alternatives on Potential Cardiotoxicity in Breast Cancer Patients

Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML

Blinatumomab Substitution Improves EFS in Pediatric High-Risk B-ALL

CD20×CD3 Bispecific Antibodies May Be Feasible Bridging Strategy in LBCL